These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 21916571)

  • 1. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nursing implications for the lifelong management of tuberous sclerosis complex.
    Agricola K; Tudor C; Krueger D; Franz DN
    J Neurosci Nurs; 2013 Aug; 45(4):226-42. PubMed ID: 23812052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible prevention of tuberous sclerosis complex lesions.
    Kotulska K; Borkowska J; Jozwiak S
    Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis.
    Komotar RJ; Starke RM; Connolly ES; Sisti MB
    Neurosurgery; 2011 Apr; 68(4):N24-5. PubMed ID: 21792104
    [No Abstract]   [Full Text] [Related]  

  • 6. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
    Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
    J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
    Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
    Moavero R; Coniglio A; Garaci F; Curatolo P
    Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
    Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
    Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
    Franz DN; Capal JK
    Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR Inhibitors in Tuberous Sclerosis Complex.
    Curatolo P; Moavero R
    Curr Neuropharmacol; 2012 Dec; 10(4):404-15. PubMed ID: 23730262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.
    Tarasewicz A; Dębska-Ślizień A; Bułanowski M; Więcek A; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2912-5. PubMed ID: 25380949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
    Palavra F; Robalo C; Reis F
    Oxid Med Cell Longev; 2017; 2017():9820181. PubMed ID: 28386314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
    Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ
    J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.